AXIM Biotechnologies, Inc. (OTC:AXIM), a diagnostic and biotechnology company developing solutions for ocular and inflammatory diseases, announced the engagement of 624 Advisors, owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch, a preeminent in vitro diagnostics (IVD) and companion diagnostics expert with over three decades of global leadership, brings deep inventor-level knowledge of AXIM’s core technology and extensive experience in FDA regulation, ISO quality systems, and clinical development.
The engagement comes at a pivotal stage for AXIM as it prepares for key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of robust quality and manufacturing infrastructure. Dr. Touch’s background uniquely aligns with these goals. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM and the inventor of the world’s first colored contact lens. He formerly headed Clinical Affairs at Bausch & Lomb and served as Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (now Syneos Health). As Chief Science Officer of an ophthalmic contract development and manufacturing organization (CDMO), he led the development of proprietary dry eye disease products, including the first eye drop addressing the Inflammatory Cascade through a novel pathway.
“This strategic engagement is an important addition to the R&D and regulatory team at AXIM,” said Catalina Valencia, President and CEO of AXIM Biotechnologies. “Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens our regulatory strategy, quality foundation, and clinical execution, while positioning AXIM for efficient global expansion and long-term operational scale.”
Dr. Touch’s advisory role is designed to provide highly qualified support across regulatory affairs, quality systems, clinical development, and manufacturing scale-up. The engagement is expected to reduce reliance on external consultants, accelerate readiness for commercialization, and enhance the company’s ability to build a milestone-based product development value proposition. His expertise spans FDA, EU Medical Device Regulation (MDR)/In Vitro Diagnostic Regulation (IVDR), and global regulatory frameworks.
“I am pleased to work with AXIM at this important stage and to continue advancing technology I originally helped develop,” said Dr. Alan J. Touch. “AXIM is building a strong foundation for market-sensitive and aware regulatory excellence and clinical credibility for its products. I look forward to supporting an excellent and cohesive scientific, marketing and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success.”
AXIM’s TearScan® platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. The company focuses on rapid, point-of-care diagnostic tests for ocular and systemic health. More information is available at www.aximbiotech.com. The original press release can be viewed at www.newmediawire.com.
